HEŽOVÁ, Renata, Ondřej SLABÝ, Petra FALTEJSKOVÁ, Zuzana MIKULKOVÁ, Ivana BUREŠOVÁ, Karthick Raja MUTHU RAJA, Jan HODEK, Jaroslava OVESNÁ and Jaroslav MICHÁLEK. microRNA-342, microRNA-191 and microRNA-510 are differentially expressed in T regulatory cells of type 1 diabetic patients. Cellular Immunology. Elsevier, 2010, vol. 2010, No 260, p. 70-74. ISSN 0008-8749.
Other formats:   BibTeX LaTeX RIS
Basic information
Original name microRNA-342, microRNA-191 and microRNA-510 are differentially expressed in T regulatory cells of type 1 diabetic patients
Name in Czech microRNA-342, microRNA-191 and microRNA-510 are differentially expressed in T regulatory cells of type 1 diabetic patients
Authors HEŽOVÁ, Renata (203 Czech Republic), Ondřej SLABÝ (203 Czech Republic, guarantor), Petra FALTEJSKOVÁ (203 Czech Republic), Zuzana MIKULKOVÁ (203 Czech Republic), Ivana BUREŠOVÁ (203 Czech Republic), Karthick Raja MUTHU RAJA (356 India), Jan HODEK (203 Czech Republic), Jaroslava OVESNÁ (203 Czech Republic) and Jaroslav MICHÁLEK (203 Czech Republic).
Edition Cellular Immunology, Elsevier, 2010, 0008-8749.
Other information
Original language English
Type of outcome Article in a journal
Field of Study 30200 3.2 Clinical medicine
Country of publisher Czech Republic
Confidentiality degree is not subject to a state or trade secret
WWW URL
Impact factor Impact factor: 2.575
RIV identification code RIV/00216224:14110/10:00040729
Organization unit Faculty of Medicine
UT WoS 000273594200003
Keywords in English microRNA; Expression profile; Regulatory T cells; Diabetes mellitus type 1
Tags International impact, Reviewed
Changed by Changed by: prof. RNDr. Ondřej Slabý, Ph.D., učo 42891. Changed: 4/8/2010 13:19.
Abstract
We performed miRNAs profiling in a population of regulatory T celss (Tregs) separated from peripheral blood of five type 1 diabetic patients and six healthy donors. For more detailed molecular char- acterisation of Tregs, we additionally compared miRNAs expression profiles of Tregs and conventional T cells. Tregs were isolated according to CD3+, CD4+, CD25hi+ and CD127low by flow cytometry, and miRNA expression profiling was performed using TaqMan Array Human MicroRNA Panel-1 (384-well low density array). In Tregs of diabetic patients we found significantly increased expression of miRNA-510 (p = 0.05) and decreased expression of both miRNA-342 (p< 0.0001) and miRNA-191 (p = 0.0079). When comparing Tregs and T cells, we revealed that Tregs had significant higher expression of miRNA-146a and lower expression of eight specific miRNAs (20b, 31, 99a, 100, 125b, 151, 335, and 365). This is the first study demonstrating changes in miRNA expression profiles occurring in Tregs of T1D patients and a miRNAs signature of adult Tregs.
Abstract (in Czech)
We performed miRNAs profiling in a population of regulatory T celss (Tregs) separated from peripheral blood of five type 1 diabetic patients and six healthy donors. For more detailed molecular char- acterisation of Tregs, we additionally compared miRNAs expression profiles of Tregs and conventional T cells. Tregs were isolated according to CD3+, CD4+, CD25hi+ and CD127low by flow cytometry, and miRNA expression profiling was performed using TaqMan Array Human MicroRNA Panel-1 (384-well low density array). In Tregs of diabetic patients we found significantly increased expression of miRNA-510 (p = 0.05) and decreased expression of both miRNA-342 (p< 0.0001) and miRNA-191 (p = 0.0079). When comparing Tregs and T cells, we revealed that Tregs had significant higher expression of miRNA-146a and lower expression of eight specific miRNAs (20b, 31, 99a, 100, 125b, 151, 335, and 365). This is the first study demonstrating changes in miRNA expression profiles occurring in Tregs of T1D patients and a miRNAs signature of adult Tregs.
Links
NR9355, research and development projectName: Imunoregulační funkce u dětských pacientů s diabetes mellitus
2B08066, research and development projectName: Studium léčebných možností diabetes mellitus 1. typu jako geneticky determinované metabolické choroby s využitím nových imunoterapeutických postupů
PrintDisplayed: 29/9/2024 09:55